Trimipramine

Contraindicated

Trimipramine Linezolid Injection Zyvox Increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes) Details Trimipramine Metoclopramide Injection Gimoti An increased risk of extrapyramidal reactions and neuroleptic malignant syndrome Details Trimipramine Metoclopramide Nasal Spray Gimoti An increased risk of extrapyramidal reactions and neuroleptic malignant syndrome Details

Major

Trimipramine Acetaminophen And Codeine Capital® & Codeine Explained Increased risk of paralytic ileus; increased risk of serotonin syndrome Details Trimipramine Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Trimipramine Sertraline Explained Increased CYP2D6 substrate exposure, an increased risk of serotonin syndrome and an increased risk of QT interval prolongation Details Trimipramine Albuterol Oral Inhalation Accuneb® Explained An increased risk of cardiovascular system effects Details Trimipramine Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of paralytic ileus Details Trimipramine Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Trimipramine Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Trimipramine Arsenic Trioxide Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Trimipramine Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Trimipramine Arsenic Trioxide Injection Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Trimipramine Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Trimipramine Aspirin Acuprin® An increased risk of bleeding Details Trimipramine Aspirin Rectal Aspirin An increased risk of bleeding Details Trimipramine Azithromycin AzaSite An increased risk of QT interval prolongation Details Trimipramine Abiraterone Abirtega Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details Trimipramine Alfuzosin UroXatral An increased risk of QT interval prolongation Details Trimipramine Anagrelide Agrylin Increased risk of QT interval prolongation Details Trimipramine Bedaquiline Sirturo Increased risk of QT interval prolongation Details Trimipramine Bromfenac Ophthalmic Bromday® An increased risk of bleeding Details Trimipramine Butorphanol Injection Butorphic Increased risk of serotonin syndrome; increased risk of respiratory and CNS depression Details Trimipramine Butorphanol Nasal Spray Stadol® NS Increased risk of serotonin syndrome; increased risk of respiratory and CNS depression Details Trimipramine Chloroquine Aralen® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Trimipramine Clonidine Transdermal Patch Catapres Reduced antihypertensive effects and may counteract the hypotensive effects of cloNIDine Details Trimipramine Dacomitinib Vizimpro Increased exposure of the CYP2D6 substrate Details Trimipramine Dasatinib Phyrago An increased risk of QT interval prolongation Details Trimipramine Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Trimipramine Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Trimipramine Diclofenac Ophthalmic Voltaren® Eye Drops An increased risk of bleeding Details Trimipramine Diclofenac Topical (Actinic Keratosis) Pennsaid An increased risk of bleeding Details Trimipramine Diclofenac Topical (Arthritis Pain) Pennsaid® An increased risk of bleeding Details Trimipramine Diclofenac Transdermal Patch Flector An increased risk of bleeding Details Trimipramine Disopyramide Norpace An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Trimipramine Dofetilide Tikosyn An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Trimipramine Dolasetron Anzemet Increased risk of serotonin syndrome and QT-interval prolongation Details Trimipramine Dolasetron Injection Anzemet Increased risk of serotonin syndrome and QT-interval prolongation Details Trimipramine Enasidenib Idhifa Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse effects Details Trimipramine Encorafenib Braftovi Increased risk of QT interval prolongation Details